Medical Devices Today

Diabetes: CGM Goes Mainstream

Article preview from Medtech Insight - July/August 2008

Continuous glucose monitoring (CGM) is moving closer to becoming a staple of effective diabetes treatment. The three companies that produce CGM devices - Medtronic, DexCom, and Abbott Laboratories - are very active in demonstrating the value of this technology, but other companies are stepping up in the market. Meanwhile, the focus on CGM is having an effect on other products, including insulin pumps. Find out more...

At-A-Glance: Device Deals, Alliances, Financing and Acquisitions - July/August 2008

Medical Devices Today has provided a roundup of the most recent device and diagnostics deals, mergers and alliances from July and August from Windhover Information and FDC Reports’ Strategic Transactions - The Device Deal Database. Our proprietary database is designed for medical technology professionals and investors that need to stay current on the latest industry alliances, financing, mergers & acquisitions and other strategic partnerships.

Eurocor In Talks With Global Stent Makers For Joint Distribution Of Next-Generation Stents

Full article reprinted from PharmAsia News - August 20, 2008

MUMBAI - A few of the world's top stent makers are in discussions with German stent manufacturer Eurocor for joint distribution of its next-generation interventional cardiovascular stents in the U.S. Find out more...

Boston Scientific Initiates Worldwide Recall of NexStent

Full article reprinted from "The Gray Sheet" - August 18, 2008

Just as Boston Scientific is beginning to emerge from the quality control cloud it has been living under for the past couple years, FDA revealed Aug. 14 that the firm has recalled its NexStent carotid artery stenting system. Find out more...

Here Comes ICD-10

Full brief reprinted from "The Gray Sheet" - August 18, 2008

Find out about CMS' newly proposed regulation to adopt ICD-10 diagnosis and procedure codes that would replace 30-year-old ICD-9, used by health care providers, payers and other stakeholders for billing, tracking and other purposes.

“Regulating Asia” Author/Attorney to Host Live Web Chat

Medical Devices Today is pleased to invite you to chat privately online with Leslie Platt, attorney at Pillsbury Winthrop Shaw Pittman LLP about his recently featured Insider Analysis report, "Regulating Asia: The Importance Of "Who" In Medical Product Regulation."

Thursday, August 21, 2008
2:00 – 4:00 pm EST
Free Online Chat with Leslie Platt, Esq.

Register for the chat online and get your complimentary download of the eight-page Insider Analysis report: The Importance Of "Who" In Medical Product Regulation. This special report examines how the outlooks of individual regulators affect performance, compliance and enforcement in Asia.

The CDRH Shuffle: Device Center Tweaks Management Personnel

Full article reprinted from "The Gray Sheet" - August 18, 2008

FDA's device center has seen a lot of jumping around this year, with more than 40 upper-level moves since January (see chart: "New Jobs Since January").

New Mass. Law Irks Industry, As Focus Shifts To Reg Implementation

Full article reprinted from "The Gray Sheet" - August 18, 2008

Find out what device industry advocates are saying about a new Massachusetts law that requires all device and drug companies doing business in the state to abide by a strict marketing code of conduct.

Regulating Asia: The Importance Of "Who" In Medical Product Regulation

Special 8-page Insider Analysis report reprinted from PharmAsia News

Complimentary download of this Insider Analysis report from Pillsbury Winthrop Shaw Pittman LLP: The Importance Of "Who" In Medical Product Regulation. This special report examines how the outlooks of individual regulators affect performance, compliance and enforcement in Asia. PLUS, find out how you can chat live online with the author!

Claim your free report - Immediate download

Saints or Saviors? Secondary Buyers Offer Exit for BSX, Others

Article preview from Start-Up - July 2008

Following the sale of Boston Scientific's venture portfolio, secondary buyers are positioning themselves as possible purchases of venture capital portfolios.